Polaryx Therapeutics, Inc
Veridion Score
BETALOW CONF · 4/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PLYX moving today?
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PLYX overview
Related filings and maps
Congress activity in PLYX
No receipt-qualified Congressional disclosure is present for PLYX in the cached public ledger.
PLYX contract awards, year to date.
Public federal awards linked to this ticker.
PLYX lobbying filings, year to date.
Registered lobbying filings matched to Polaryx Therapeutics, Inc.